scholarly journals Effectiveness and Limitations of β-Blocker Therapy in Congenital Long-QT Syndrome

Circulation ◽  
2001 ◽  
Vol 103 (4) ◽  
Author(s):  
Robert M. Gow
Keyword(s):  
Long Qt Syndrome ◽  
Long Qt ◽  
Blocker Therapy ◽  
Β Blocker ◽  
Qt Syndrome ◽  
Congenital Long Qt Syndrome

scholarly journals Effectiveness and Limitations of β-Blocker Therapy in Congenital Long-QT Syndrome

Circulation ◽  
2000 ◽  
Vol 101 (6) ◽  
pp. 616-623 ◽  
Author(s):  
Arthur J. Moss ◽  
Wojciech Zareba ◽  
W. Jackson Hall ◽  
Peter J. Schwartz ◽  
Richard S. Crampton ◽  
...  
Keyword(s):  
Long Qt Syndrome ◽  
Long Qt ◽  
Blocker Therapy ◽  
Β Blocker ◽  
Qt Syndrome ◽  
Congenital Long Qt Syndrome

Sports participation in long QT syndrome

2017 ◽  
Vol 27 (S1) ◽  
pp. S43-S48 ◽  
Author(s):  
Peter F. Aziz ◽  
Elizabeth V. Saarel
Keyword(s):  
Long Qt Syndrome ◽  
Scientific Evidence ◽  
Sports Participation ◽  
Athletic Activity ◽  
Long Qt ◽  
Blocker Therapy ◽  
Complex Interactions ◽  
Β Blocker ◽  
Qt Syndrome ◽  
Congenital Long Qt Syndrome

AbstractUntreated congenital long QT syndrome may result in potentially lethal ventricular tachycardia. In the most common type, risk of such an event has been linked to exercise. This originally resulted in very restrictive guidelines for sports participation in affected individuals. Although the complex interactions of a specific genotype, modifying cofactors, and risk are only now being explored, scientific evidence based on clinical experience now suggests that in many instances such restrictive guidelines are unwarranted. In particular, patients with this condition who are compliant with β-blocker therapy and who have never had symptoms during exertion are now enjoying the benefits of athletic activity.

Gene-based β-blocker therapy for long-QT syndrome type 2: comparison between Nadolol and Propranolol

2019 ◽  
Vol 53 ◽  
pp. e1
Author(s):  
Chisato Okamoto ◽  
Takeshi Aiba ◽  
Tsukasa Kamakura ◽  
Mitsuru Wada ◽  
Kenichiro Yamagata ◽  
...  
Keyword(s):  
Long Qt Syndrome ◽  
Syndrome Type ◽  
Long Qt ◽  
Blocker Therapy ◽  
Β Blocker ◽  
Qt Syndrome

Arrhythmia risk and β-blocker therapy in pregnant women with long QT syndrome

Heart ◽  
2017 ◽  
Vol 103 (17) ◽  
pp. 1374-1379 ◽  
Author(s):  
Kohei Ishibashi ◽  
Takeshi Aiba ◽  
Chizuko Kamiya ◽  
Aya Miyazaki ◽  
Heima Sakaguchi ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Long Qt Syndrome ◽  
Long Qt ◽  
Blocker Therapy ◽  
Β Blocker ◽  
Qt Syndrome

Gene-based β-blocker therapy for long-QT syndrome type 2: comparison between Nadolol and Propranolol

2018 ◽  
Vol 51 (6) ◽  
pp. 1161
Author(s):  
Chisato Okamoto ◽  
Takeshi Aiba ◽  
Tsukasa Kamakura ◽  
Mitsuru Wada ◽  
Kenichiro Yamagata ◽  
...  
Keyword(s):  
Long Qt Syndrome ◽  
Syndrome Type ◽  
Long Qt ◽  
Blocker Therapy ◽  
Β Blocker ◽  
Qt Syndrome

scholarly journals Management of Long QT Syndrome in Women Before, During, and After Pregnancy

2021 ◽  
Vol 15 ◽  
Author(s):  
Caroline Taylor ◽  
Bruce S Stambler
Keyword(s):  
Long Qt Syndrome ◽  
Postpartum Period ◽  
Torsades De Pointes ◽  
Close Monitoring ◽  
Cardiac Events ◽  
Long Qt ◽  
Life Threatening ◽  
Β Blocker ◽  
Qt Syndrome ◽  
Congenital Long Qt Syndrome

Congenital long QT syndrome (LQTS) is a primary genetic and electrical disorder that increases risk for torsades de pointes, syncope, and sudden death. Post-pubertal women with LQTS require specialized multidisciplinary management before, during, and after pregnancy involving cardiology and obstetrics to reduce risk for cardiac events in themselves and their fetuses and babies. The risk of potentially life-threatening events is lower during pregnancy but increases significantly during the 9-month postpartum period. Treatment of women with LQTS with a preferred β-blocker at optimal doses along with close monitoring are indicated throughout pregnancy and during the high-risk postpartum period.

scholarly journals Management of Congenital Long-QT Syndrome: Commentary From the Experts

2021 ◽  
Author(s):  
Elizabeth S. Kaufman ◽  
Lee L. Eckhardt ◽  
Michael J. Ackerman ◽  
Peter F. Aziz ◽  
Elijah R. Behr ◽  
...  
Keyword(s):  
Long Qt Syndrome ◽  
Intermediate Risk ◽  
Long Qt ◽  
Divergence Of Opinion ◽  
Clinical Scenarios ◽  
Key Points ◽  
Therapeutic Measures ◽  
Β Blocker ◽  
Qt Syndrome ◽  
Congenital Long Qt Syndrome

While published guidelines are useful in the care of patients with long-QT syndrome, it can be difficult to decide how to apply the guidelines to individual patients, particularly those with intermediate risk. We explored the diversity of opinion among 24 clinicians with expertise in long-QT syndrome. Experts from various regions and institutions were presented with 4 challenging clinical scenarios and asked to provide commentary emphasizing why they would make their treatment recommendations. All 24 authors were asked to vote on case-specific questions so as to demonstrate the degree of consensus or divergence of opinion. Of 24 authors, 23 voted and 1 abstained. Details of voting results with commentary are presented. There was consensus on several key points, particularly on the importance of the diagnostic evaluation and of β-blocker use. There was diversity of opinion about the appropriate use of other therapeutic measures in intermediate-risk individuals. Significant gaps in knowledge were identified.

Sign in / Sign up

Export Citation Format

Share Document